Austerity Holds Back VC Investing in European Biotech Companies in 2011

By John Davis / Email the Author / “The Pink Sheet” Jan. 23, 2012, Vol. 74, No. 4
Year In Review And The Year Ahead / Word Count: 1009 / Article # 00120123015

Executive Summary

Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 1009-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Austerity Holds Back VC Investing in European Biotech Companies in 2011

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Pink Sheet” will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Austerity Holds Back VC Investing in European Biotech Companies in 2011

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 7

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article